『Beta Finch - Income & Dividends - EN』のカバーアート

Beta Finch - Income & Dividends - EN

Beta Finch - Income & Dividends - EN

著者： Beta Finch
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
Reliable dividend payers popular with income-focused investors. AI-powered earnings call analysis for Income & Dividends (INCOME). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch 個人ファイナンス 経済学
エピソード
  • Johnson & Johnson Q3 2026 Earnings Analysis

    Johnson & Johnson Q3 2026 Earnings Analysis
    2026/10/15
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're diving into Johnson & Johnson's third quarter 2026 results, reported Tuesday. Before we get going, a quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: And there's a lot to unpack here, Alex, because on the surface this looks like a messy quarter, but underneath it's actually a pretty strong one.

    ALEX: Right, let's start with the headline numbers. J&J posted $25.4 billion in revenue for Q3, up 6% operationally, which actually beat analyst expectations. Management raised full-year guidance and now expects full-year operational sales growth of 6.7% to 7.1%, putting them on track to cross $100 billion in annual revenue for the very first time in the company's 140-year history.

    JORDAN: That's a huge milestone. But here's where it gets messy — GAAP net earnings were just $210 million, and diluted EPS came in at nine cents, compared to $2.12 a year ago. That's a massive drop.

    ALEX: And the reason is a one-time hit, not a business problem. J&J took a $5.5 billion charge tied to resolving the ovarian talc litigation, plus costs from two acquisitions — Firefly Bio in oncology and a collaboration with Cell BioMedicine in cell therapy. Strip those out, and adjusted EPS was $2.59, down about 7.5% year-over-year, but mostly because of those deal-related expenses, not underlying weakness.

    JORDAN: Exactly. The core business is actually accelerating. Innovative Medicine — that's their pharma segment — grew 7.9% operationally to $16.8 billion, with eight brands growing double digits. Oncology alone grew 17%.

    ALEX: Let's talk about the stars of the show. Tremfya, their immunology drug, grew 68% in the quarter. CARVYKTI, their multiple myeloma cell therapy, up 35%. And RYBREVANT, for lung cancer, up 64%. Tom Cavanaugh, the head of Innovative Medicine, specifically called out Icotrokinra — their new oral psoriasis treatment — saying it's tracking better than almost any launch they've seen in psoriatic disease, with over 20,000 patients started in just months.

    JORDAN: What stood out to me is they're calling this a path to double-digit growth by 2030, and when an analyst from Goldman pressed CFO Joe Wolk on whether that assumes big acquisitions, he was pretty direct — no, it's organic. That's a meaningful claim given how reliant a lot of pharma growth stories are on M&A.

    ALEX: Now, MedTech is the other side of the story, and it's where things got rockier. That division only grew 2.5%, missing expectations. Management was candid about it — Timothy Schmid, who runs MedTech, basically said "our performance is below the standard we set internally."

    JORDAN: Two specific problem areas: international markets, especially due to disruption from the Middle East conflict affecting hospital purchasing and tender timing, and Abiomed, their heart pump business, which actually declined 1.5% because of a disputed study on high-risk PCI procedures. Execs pushed back hard on that study's methodology.

    ALEX: But it wasn't all bad news in MedTech. Shockwave, their cardiovascular device business, grew 17%. And they got FDA clearance for Ottava, their new surgical robot — first commercial customer already signed. That's a big long-term bet on competing with Intuitive Surgical in robotics.

    JORDAN: One housekeeping item investors should note — J&J confirmed they're still on track to spin off their orthopedics business, DePuy Synthes, by mid-2027, and they're leaning toward a straight spin-off rather than a sale.

    ALEX: Let's hit a couple of Q&A highlights. On Icotrokinra,

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • PepsiCo Q3 2026 Earnings Analysis

    PepsiCo Q3 2026 Earnings Analysis
    2026/10/08
    More earnings analysis: https://betafinch.com
    Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into PepsiCo's third quarter 2026 results, reported October 8th. Before we jump in, quick reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: And there's a lot to unpack here, Alex, because this is one of those quarters where the headline numbers look fine, but the guidance cut tells a very different story.

    ALEX: Right, let's start with the numbers. Organic revenue grew 3.1% — that's actually the fastest growth rate PepsiCo has posted since Q4 2023. Reported revenue was north of 5%. Core operating profit was up 3%, and EPS grew 2%.

    JORDAN: Those top-line numbers are genuinely good news, especially the fact that it was volume-led — global beverage volume up 3%, global snacks volume up 4% excluding a commodity-heavy South Africa grains business. But here's the catch: PepsiCo lowered its full-year EPS guidance, and it's entirely margin-driven.

    ALEX: Right, so let's split this into the two stories — international, which is firing on all cylinders, and North America, which is clearly the problem child. CFO Steve Schmitt said international organic revenue grew 8% with operating margin expansion of 105 basis points. CEO Ramon Laguarta noted international is now 45% of the company's profit year-to-date.

    JORDAN: That's a massive shift in the company's center of gravity. Meanwhile in North America, it's a mixed bag. Foods — meaning the Frito-Lay snacks business — actually improved sequentially. Laguarta made a point of saying that last year snacks volume was negative low-single-digits, and this year it's flipped to positive low-single-digit growth. He credits the price reset strategy plus innovation platforms like portion-controlled packs and the "permissible" portfolio — think SunChips, Smartfood, PopCorners, Simply.

    ALEX: But beverages in North America is where things get ugly. Schmitt said the beverage business actually decelerated in the quarter. Laguarta was blunt about it — he said they're competing well in hydration and energy, pointing to Gatorade, Propel, and the pending integration of Alani Nu and Celsius, but they are explicitly "not competing well" in soft drinks, meaning Pepsi, Mountain Dew, and that whole core carbonated lineup.

    JORDAN: And that word kept coming up over and over — "urgency." Multiple analysts pushed on what that actually means in practice, because it's easy to say urgency and mean nothing. Laguarta's answer was essentially twofold: cut every cost that isn't tied to growth — overhead, corporate unallocated spending, duplications — and reinvest that money into A&M, advertising and marketing, behind the core brands. He also name-checked a new partnership with Publicis for more data-driven, targeted marketing.

    ALEX: Now let's talk about why guidance actually got cut, because this is the part investors should really sit with. Schmitt said input costs are trending higher than expected, mix has been a headwind, and — this is a detail that's easy to miss — PepsiCo got a tariff-related benefit in North America beverages in Q3 that won't repeat in Q4. So that's a double hit: inflation ramping as hedges roll off, plus losing a one-time tariff tailwind.

    JORDAN: And importantly, they're not pulling back on investment to protect the bottom line. Schmitt was explicit that A&M spending actually increased in both international and North America this quarter — double-digit increases in the U.S., in fact. So the margin pressure is a deliberate choice to keep funding growth rather than a sign the business is falling apart.

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • McDonald's Q2 2026 Earnings Analysis

    McDonald's Q2 2026 Earnings Analysis
    2026/08/29
    More earnings analysis: https://betafinch.com
    Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into McDonald's second quarter 2026 results, and there's a lot to unpack — some real strategic news alongside a leadership change. Before we get into it, quick note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Yeah, and this one's juicy, Alex — because it's not the usual "everything's great" call. McDonald's actually came out and said, in Chris Kempczinski's words, "we don't have a strategy problem, we simply didn't execute."

    ALEX: Right, so let's start with the numbers. Systemwide sales grew 4% in constant currency, global comparable sales up 1.3%. Adjusted EPS came in at $3.38, up 5% on a constant currency basis. Solid, but not spectacular.

    JORDAN: And the real story is the U.S. — comp sales grew just 0.8% in the quarter, which was below expectations. International actually carried the day here, with IOM up 1.5% and the international developmental licensed markets up 1.9%, led by Japan posting its tenth straight quarter of positive guest counts.

    ALEX: So what actually went wrong in the U.S.? CFO Ian Borden broke it into pieces. They launched this new "everyday affordable price" menu — 10 items under $3 — in late April, but execution was spotty. Only about 60 to 65% of restaurants actually followed the recommended pricing.

    JORDAN: And here's the kicker — to fund that value push, they pulled back on digital offers and killed the Buy One, Add One for a dollar promotion, which apparently really annoyed their most loyal, high-frequency customers. Kempczinski flat-out called it "a bad trade."

    ALEX: Management said that alone accounted for about two-thirds of the traffic miss. The rest came down to their FIFA-themed marketing campaign in June underperforming expectations.

    JORDAN: There was also this operational overload problem — Chris painted a great picture of it, basically saying "put yourself in a restaurant manager's shoes." You've got K-Pop Demon Hunters merchandise going up, then three weeks later you're flipping the value menu, then a brand-new beverage platform launches, then FIFA. Crew members are getting whiplash, service times went up, satisfaction scores went down.

    ALEX: It's a good reminder that even a company with McDonald's scale and marketing muscle can trip over its own to-do list. Too much "new" at once, poorly sequenced.

    JORDAN: Right, and it bled into July too — Borden mentioned U.S. comps were actually slightly negative to start Q3. So this isn't fully behind them yet.

    ALEX: Now here's where it gets interesting — there's a leadership shakeup. Skye Anderson, previously COO of McDonald's USA, is stepping in as the new President of McDonald's U.S., effective immediately. Joe Erlinger, who ran the U.S. business for nearly seven years, is leaving the company.

    JORDAN: Chris was pretty deliberate about framing this as a planned transition, not a panic move — he name-checked Anderson's 26-year track record, including a stint leading the U.S. West zone where she drove over 30% comp sales growth. But the timing, right after a rough quarter, is obviously going to raise eyebrows.

    ALEX: On the brighter side — beverages. McDonald's launched a new beverage platform in the U.S., Canada, and Germany in May, and early results are beating expectations. Higher checks, strong food attachment, and more than half the traffic is coming after the lunch rush — which is exactly the low-volume window they want to fill.

    JORDAN: They're also leaning into Red Bull Energizers rolling out in the U.S. soon, and Australia just launched the platform in mid-July. This seems like a l

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません